INFLAZOME
21.9.2020 08:02:10 CEST | Business Wire | Press release
Inflazome announced today that it has closed a share purchase agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) in which Inflazome’s shareholders received an upfront payment of €380 million, and are eligible to receive additional contingent payments to be made based on the achievement of certain predetermined milestones.
Inflazome was founded in 2016 by leading medical researchers Prof Matt Cooper (University of Queensland, Australia) and Prof Luke O’Neill (Trinity College Dublin, Ireland). The company is a leader in the development of inflammasome inhibitors.
The acquisition gives Roche full rights to Inflazome’s entire portfolio which is composed of clinical and preclinical orally available small molecule NLRP3 inhibitors. Roche intends to further develop NLRP3 inhibitors across a wide variety of indications with high unmet medical need.
Matt Cooper, Chief Executive Officer, Inflazome, commented: “We are delighted to close this deal with Roche, an outstanding pharmaceutical company with a broad commitment to multiple indications. With Inflazome now part of the Roche organization, Inflazome’s pioneering molecules are well positioned to be developed quickly and effectively so they can help patients suffering from debilitating diseases.”
Manus Rogan, Chairman and co-founding investor of Inflazome, said: “It has been a privilege to work alongside Matt, his team and my co-investors. The Company, which was established just four years ago, developed a portfolio of clinical and pre-clinical molecules with a lean, highly experienced team and limited invested capital.”
Lazard acted as financial advisor and Goodwin Procter and Byrne Wallace acted as legal counsel to Inflazome.
About Inflazome
Inflazome is a biotech company leading the development of orally available drugs to address clinical unmet needs in inflammatory diseases by targeting inflammasomes. Inflammasomes are understood to drive many chronic inflammatory conditions, from Parkinson’s and Alzheimer’s to asthma, inflammatory bowel disease, chronic kidney disease, cardiovascular disease, arthritis and NASH. Inflazome has a portfolio of orally available small molecule NLRP3 inhibitors, with lead molecules having successfully completed Phase I clinical trials, as well as several high potential earlier-stage programmes.
Inflazome has raised €55m in Venture Capital financing from leading investors Forbion, Longitude Capital, Fountain Healthcare Partners and Novartis Venture Fund.
Inflazome is headquartered in Dublin, Ireland.
About the NLRP3 Inflammasome
Activated NLRP3 acts as a ‘danger sensor’ in the body to release the pro-inflammatory cytokines IL-1β, IL-18 and induce uncontrolled, lytic cell death (pyroptosis). These processes lead to chronic inflammation, and as such, NLRP3 has been implicated in a large number of diseases.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200920005066/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SES: Full Year 2025 Results2.3.2026 07:30:00 CET | Press release
SES S.A. fully consolidates Intelsat from 17 July 2025 and announces financial results for the year ended 31 December 2025 FY25 Performance (€ million) 2025 as reported (1) 2024 as reported (1) ∆ at constant FX (2) 2025 like-for-like (3) 2024 like-for-like (3) ∆ at constant FX (2) Average €/$ FX rate 1.12 1.09 1.12 1.09 Revenue (4) 2,627 2,001 +33.9% 3,512 3,656 -1.6% Adjusted EBITDA (4) (5) 1,196 1,028 +19.1% 1,529 1,783 -12.1% 1) ‘Reported basis’ with Intelsat fully consolidated from 17 July 2025 2) ‘At constant FX’ refers to comparative figures restated at the current period FX to neutralise currency variations 3) ‘Like-for-like basis’ as if Intelsat fully consolidated from 1 January 2024 4) Full-year 2025 results include the effects of purchase price accounting (PPA) related to Intelsat acquisition: Negative impact of €6m on revenue & €8m on Adj. EBITDA 5) Excluding operating expenses/income recognised in relation to U.S. C-band repurposing, other income non-recurring, fair value m
Airgain and Nextivity Enter Strategic Partnership on Co-developing Next Generation Integrated 4G / 5G Solutions2.3.2026 07:30:00 CET | Press release
Airgain, Inc. (NASDAQ: AIRG), a leading provider of wireless connectivity solutions, and Nextivity, Inc., an industry leader in intelligent cellular coverage solutions, today announced they have entered into a Strategic Partnership Agreement to collaborate on the development of integrated solutions aimed at improving 4G and 5G coverage across challenging indoor and outdoor environments. The agreement establishes a structured framework for Airgain and Nextivity to jointly define and co-develop integrated coverage solutions that leverage Airgain’s Lighthouse™ 5G Intelligent Node platform and Nextivity’s GO family of intelligent repeaters powered by Nextivity’s IntelliBoost® processor to enhance 4G and 5G coverage solutions beyond the walls of a building. Large Market Opportunity & Accelerated Go‑to‑Market Execution Industry demand for intelligent 4G and 5G coverage-extension solutions continues to accelerate as operators, enterprises, and public safety organizations expand network densif
NTT DOCOMO BUSINESS and Airlinq Form Strategic Partnership for Global IoT2.3.2026 07:00:00 CET | Press release
NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation; Headquarters: Chiyoda-ku, Tokyo; President and CEO: Katsushige Kojima; “NTT DOCOMO BUSINESS”) and Airlinq Inc. (Headquarters: California, USA; CEO: Sunil Kaul; “Airlinq”), a global provider of AIoT solutions and Autonomous Connectivity Management Platform (CMP)1, have entered into a strategic partnership to expand the delivery of global IoT-connected solutions across markets with diverse and country-specific telecommunications regulatory requirements2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260301475708/en/ Conceptual Overview of This Partnership 1. Background Global deployment of IoT-enabled devices and services continues to accelerate, particularly across mobility industries such as automotive and construction machinery. As connected services—including connected vehicles3—expand across borders, enterprises increasingly require reliable connectivity
PHCbi Launches LiCellGrow™ Cell Expansion System to Support High-Quality and Efficient Production of Cell and Gene Therapies2.3.2026 06:12:00 CET | Press release
— Proprietary In-Line Monitoring Technology Enables Seamless Scale-Up from Basic Research to Commercial Manufacturing — PHC Corporation’s Biomedical Division (Head Office: Chiyoda-ku, Tokyo; President: Nobuaki Nakamura; hereinafter “PHCbi”), a global provider of laboratory sample storage and cell cultivation solutions and subsidiary of PHC Holdings Corporation (Head Office: Chiyoda-ku, Tokyo), today announced the launch of its new cell expansion system LiCellGrow™ (*1) for research use in Japan and other select countries worldwide(*2). The system is designed to improve quality and efficiency in the production of new advanced therapies by allowing therapy developers to visualize metabolic changes in cells in real time and automatically control culture conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260301429276/en/ Controller and processor, Filter-less culture bag and reservoir/waste bags *Controller and other acce
Corning Launches Corning® Gorilla® Glass Ceramic 3 with Enhanced Drop Durability2.3.2026 06:05:00 CET | Press release
Motorola will feature the advanced cover material on its next-generation foldable device. Corning Incorporated (NYSE: GLW) today announced the launch of Corning® Gorilla® Glass Ceramic 3, the toughest Gorilla Glass Ceramic ever made. Designed to help deliver enhanced durability across a device’s lifetime, Gorilla Glass Ceramic 3 will be featured on Motorola’s upcoming razr fold device. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260227039398/en/ Corning® Gorilla® Glass Ceramic 3 is the toughest Gorilla Glass Ceramic ever made. “We engineer our materials with longevity in mind, not just initial performance,” said Lori Hamilton, Division Vice President & Business Technology Director, Corning® Gorilla® Glass. “With our unparalleled expertise in glass and ceramic science, we built Gorilla Glass Ceramic 3 to provide consistent, reliable durability that holds up over time.” Consumer devices are routinely exposed to a variety of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom